commercialization

By Dave Muoio 04:53 pm September 11, 2020
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said. Employing cognitive and neurobehavioral...